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In this study, we have shown that there are seasonal differences in the onset of the (Epstein–Barr virus) EBV-positive and -negative
forms of paediatric Hodgkin’s lymphoma (HL). This suggests aetiological differences between the two forms of this disease. EBV-
positive HL might be a rare consequence of primary EBV infection.
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The Epstein–Barr virus (EBV) is detectable in the malignant
Hodgkin/Reed-Sternberg (HRS) cells in approximately 50% of
cases of paediatric Hodgkin’s lymphoma (HL) from the UK (Flavell
et al, 2000). Although EBV is likely to play a pathogenic role in
virus-associated HL cases, this has yet to be demonstrated. The
striking epidemiological differences between EBV-positive and -
negative paediatric HL (Weinreb et al, 1996; Glaser et al, 1997)
Flavell et al, 2000) have been used to support the view that these
two forms of HL are aetiologically distinct. A recent study by
Westerbeek et al (1998) reported the more frequent onset of
paediatric HL in the winter months, with a significant peak in
December. Here we have investigated whether such seasonal effects
are associated with EBV status.
MATERIALS AND METHODS
The study population comprised all cases of histologically
confirmed HL in children (o15 years) diagnosed in the West
Midlands National Health Service Region, UK between 1957 and
2001. Patient data (age, date of diagnosis, sex, histological subtype,
ethnic group and social class (based on father’s occupation)) were
extracted from medical notes by the West Midlands Regional
Children’s Tumour Registry (WMRCTR). Histological subtype was
classified according to the Rye system (Lukes et al, 1966) and
based upon expert histology as reported elsewhere (Parkes et al,
1997). Epstein–Barr virus status was determined by immunohis-
tochemistry for LMP1 expression as previously described (Murray
et al, 1992). Hospital notes, including general practitioner referral
letters, histology reports and patient discharge summaries were
examined to retrieve the date of onset of disease defined as the first
appearance of symptoms. The lag time between the onset of
symptoms and the date of diagnosis (defined as the date of
histological diagnosis) was also recorded. A w
2 test was used to test
the null hypothesis that EBV-positive and EBV-negative HL cases
were equally distributed across the year. For this analysis, cases
were divided into those with an onset in the summer (May–
October) and winter (November–April) as described by Wester-
beek et al (1998). Cochran’s test was used to adjust for the effects
of ethnic group, social class, age and histological subtype (factors
associated with EBV status; Flavell et al, 2000)) on this analysis.
Edwards’ test, which looks for a one-cycle sinusoidal deviation
from the null distribution (Walter, 1977; Westerbreek et al, 1998),
was also used to identify any seasonal differences based on EBV
status.
RESULTS
There were 233 cases of HL in children recorded within the study
area between 1957 and 2001. Reliable data concerning the onset of
symptoms were available in 172 cases. Epstein–Barr virus status
was unknown in 31 of these cases. Of the 141 tumours, 69 (48.9%)
were EBV-positive. The median lag time was 12.35 weeks, although
there was considerable variation in lag times; 15% of patients had a
lag time up to 4 weeks duration, 35% of cases had a lag time
between 1 and 3 months, and in 25% of cases the duration between
onset of symptoms and diagnosis was between 4 and 6 months.
The remaining 25% of patients had a lag time in excess of 6
months. Analysis of all 172 HL cases using Edward’s method
revealed no significant seasonal trends in the date of onset of
symptoms (P¼0.94). More (44 out of 69; 63.8%) EBV-positive
patients reported first symptoms in the summer months, whereas a
higher proportion of EBV-negative patients (44 out of 72; 61.1%)
reported the onset of symptoms in the winter. This difference was
statistically significant (P¼0.005). A significant association
between summer onset and EBV-positive tumours remained after
stratification by sex (P¼0.008), ethnic group (white vs non-white,
P¼0.003), social class (manual, nonmanual, unknown P¼0.004),
age (0–9 years, 10–14 years, P¼0.005) and histological subtype
(lymphocyte predominant, nodular sclerosing, mixed cellularity,
other/unknown, P¼0.011). Received 29 April 2003; revised 18 July 2003; accepted 21 July 2003
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method revealed a highly significant peak onset of symptoms for
EBV-positive patients occurring at the end of July/early August
(y¼311þ1801¼2111) with a trough at the beginning of February
(y¼311)( P¼0.0093; Figure 1). The amplitude of the peak was
52%. Edward’s test failed to identify any significant seasonal
variation in the EBV-negative subgroup (P¼0.13). No seasonal
trends were observed based on the date of diagnosis, nor when the
patients were subdivided on the basis of age, sex or histological
subtype.
DISCUSSION
This is only the second study to investigate seasonal variation in
the onset of symptoms in paediatric HL. The first such study
detected a significant peak of disease onset in December, but did
not stratify patients on the basis of EBV status. Using similar
methodology and patient numbers, we failed to detect any
significant seasonal variations in the onset of symptoms for our
group of paediatric HL patients as a whole. However, when EBV-
positive and -negative patients were examined separately, a
significant peak in the onset of symptoms during July/August
was observed for the EBV-positive subgroup.
A number of infective and noninfective diseases exhibit seasonal
variation and these seasonal rhythms can be attributed to
aetiological precipitating factors. In the case of EBV-positive
paediatric HL, this aetiological event might be primary EBV
infection. Thus, the circannual rhythm in paediatric HL presenta-
tion could be due to a peak in the incidence of primary EBV
infection occurring some months prior to the development of the
tumour with the incubation period from infection to tumour
development being relatively constant. Our data are consistent
with the possibility that EBV-positive HL is the rare consequence
of exposure to this viral agent as has been previously suggested
(Parkes et al, 1994). Although Edwards’ test failed to detect any
significant seasonal variation in the EBV-negative subgroup, these
patients were significantly more likely to experience the onset of
symptoms in the winter months. This might support the view that
EBV-negative HL is associated with as an yet unidentified
infectious agent (Armstrong et al, 1998).
The relative proportion of EBV-positive and -negative HL
patients in a population group might determine whether any
seasonal effects are identifiable when these patients are combined
in the analysis. Westerbeek et al (1998) might have detected a peak
of HL onset in the winter months because of greater numbers
of EBV-negative patients. Unfortunately, EBV status was not
recorded in their study and we are unable to confirm this
possibility.
The majority of studies to investigate seasonality in HL to date
have utilised the date of diagnosis as a measure of disease onset
(Newell et al, 1985; Douglas et al, 1996, 1998). However, the highly
variable time between the onset of symptoms and the date of
diagnosis (lag time), which was confirmed in our analysis, means
that the use of date of diagnosis as a measure of disease onset
could be less reliable. However, we acknowledge that problems in
recording or recall could contribute to inaccuracies in studies that
employ date of onset of symptoms as a measure of disease onset.
In summary, our results demonstrate a significant peak in the
onset of symptoms for EBV-positive paediatric HL during the
summer months and provide evidence in support of the view that
EBV-positive HL might be a rare consequence of primary EBV
infection. Our results also provide further evidence for aetiological
differences between the EBV-positive and -negative forms of
paediatric HL.
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Figure 1 Peak in the onset of EBV-positive paediatric Hodgkin’s
lymphoma. Edwards’ method revealed a highly significant peak onset of
symptoms for EBV-positive patients occurring at the end of July/early
August (y¼31þ180¼2111) with a trough at the beginning of February
(y¼311)( P¼0.0093).
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